The Politics of Women’s Eggs
By Diane Tober,
Undark
| 06. 10. 2016
Untitled Document
A curious battle is being waged over women’s bodies in the state of California. It’s not, as one might expect, the ongoing fight over women’s rights to abortion, which I fully support. Rather, the dispute involves a woman’s right to donate her eggs for use in scientific research — and to be compensated for it. And while the clash is usually characterized as one that pits a conservative definition of “life” against a liberal embrace of a “woman’s rights to choose,” the core issues here are much more complex.
The fight began in 2004, when California voters passed Proposition 71. This initiative made stem cell research in the state a constitutional right, but state legislators — following ethical guidelines developed by the National Academy of Sciences with regard to eggs donated for stem cell research — incorporated restrictions on donor compensation. Chapter 2. Section 12355 of the California Health and Safety Code currently states:
No payment in excess of the amount of reimbursement of direct expense incurred as a result of the procedure shall be made to any subject to...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...